FutureTech II to merge with Longevity Biomedical
04/09/25, 7:49 PM
Location
delawareIndustry
biotechnology
health care
FutureTech II Acquisition Corp. has entered into a merger agreement with Longevity Biomedical Inc. The merger will transform Longevity into a wholly-owned subsidiary. The combined company is expected to list on Nasdaq under the symbol 'LBIO'. This move aligns with FutureTech's strategy of targeting innovative companies in the technology sector.
Company Info
Location
Delaware, United States
Company info
FutureTech II Acquisition Corp. is a blank check company focused on the disruptive technology sector in the U.S. The company was incorporated in Delaware in 2021 with the purpose of effecting a merger or similar business combination. It completed its Initial Public Offering in 2022, raising $115 million. FutureTech targets private companies with positive cash flow or compelling technology.